CLDX (Celldex Therapeutics) Institutional Ownership: 98.39% (As of Jul. 03, 2026)


CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $38.37
GF Value $7.08
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Institutional Ownership?

Celldex Therapeutics CLDX +4.32% 57 Institutional Ownership is 98.39% as of Jul. 03, 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $7.08 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celldex Therapeutics's institutional ownership is 98.39%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celldex Therapeutics's Insider Ownership is 8.52%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celldex Therapeutics's Float Percentage Of Total Shares Outstanding is 84.25%.

Celldex Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Institutional Ownership Chart

Celldex Therapeutics Historical Data

The historical data trend for Celldex Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 60.03 59.19 59.33 62.53 60.48 60.33 58.25 52.41 52.30 53.17
CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 98.39% mean?
Celldex Therapeutics (CLDX) has a Institutional Ownership of 98.39% as of Jul. 03, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Institutional Ownership too high?
Celldex Therapeutics' current Institutional Ownership is 98.39%. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Institutional Ownership compare to TARS and KLRA?
Celldex Therapeutics' Institutional Ownership of 98.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Institutional Ownership is 98.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.08, compared to a current price of $38.37 — trading 441.9% above its estimated fair value. The current Institutional Ownership is 98.39%. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Institutional Ownership is 98.39% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $38.37 is trading 441.9% above its estimated GF Value™ of $7.08. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Institutional Ownership: 98.39%
  • GF Value™: $7.08 vs. price of $38.37 (441.9% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.37
Price
$7.08
GF Value